Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8298MR)

This product GTTS-WQ8298MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8298MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15239MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ15851MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ13917MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ1162MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ2075MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ13943MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ12426MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW